CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Rigel Pharmaceuticals (RIGL) announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback